Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 3/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 13/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607135 | 0.84 | HDAC6 (0.58) | GRNSORT1 | |
| SCHEMBL1606876 | 0.78 | MEN1 (0.51) | TP53SMN1; SMN2 | |
| SCHEMBL1017 | 0.76 | GRN (0.43) | GRNSORT1 | |
| SCHEMBL7373270 | 0.73 | GRN (0.56) | GRNSORT1SMN1; SMN2 | |
| Bicarbonate SCHEMBL3431862 | 0.72 | PNMT (0.52) | TP53SMN1; SMN2 | |
| SCHEMBL28251767 | 0.71 | ALDH1A1 (0.41) | GRNSORT1 | |
| SCHEMBL24283666 | 0.71 | GRN (0.76) | GRNSORT1SMN1; SMN2 | |
| SCHEMBL653730 | 0.70 | SMN1; SMN2 (0.54) | SMN1; SMN2 | |
| SCHEMBL6258641 | 0.70 | MAPT (0.64) | GRNSORT1CCR2 | |
| SCHEMBL727 | 0.70 | POLB (0.51) | GRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148413-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7812043-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| EP-1689392-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049019-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | GALK1, GCKR, GCK | GRN 2453/4885SORT1 4806/4885ABCB11 4009/4885 |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | GCKR, GCK, GALK1 | GRN 3735/4885SORT1 4707/4885ABCB11 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.